Probes For Detection Of Animal Nucleotide Sequences Patents (Class 536/24.31)
-
Publication number: 20130210900Abstract: Two genes, ARID1A (AT-rich interactive domain-containing protein 1A) and PPP2R1A (protein-phosphatase 2, regulatory subunit 1, alpha), can be used in methods which are useful for detecting cancer, diagnosing cancer, contributing to a diagnosis of cancer, confirming a diagnosis of cancer, identifying appropriate treatments for cancer, monitoring treatment of cancer, and evaluating treatment protocols for cancer, including ovarian clear cell carcinoma, breast cancer, colon cancer, gastric cancer, lung cancer, medulloblastoma, pancreatic cancer, and prostate cancer.Type: ApplicationFiled: September 6, 2011Publication date: August 15, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bert Vogelstein, Kenneth W. Kinzler, Victor Velculescu, Nickolas Papadopoulos, Sian Jones
-
Publication number: 20130203052Abstract: This invention relates generally to methods for detecting cell damage as a consequence of pathophysiological or traumatic insults such as in a nuclear accident, bioterror attack, tumorigenesis, infections or in individuals with cardiovascular disease.Type: ApplicationFiled: November 20, 2012Publication date: August 8, 2013Applicant: DIACARTA LLCInventor: DiaCarta LLC
-
Publication number: 20130203060Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: ApplicationFiled: April 1, 2013Publication date: August 8, 2013Applicant: Merck Sharp & Dohme Corp.Inventor: Merck Sharp & Dohme Corp.
-
Patent number: 8501401Abstract: An isolated steroidogenesis modified cell comprising one or more steroid biosynthesis knock down nucleic acid operatively linked to a promoter, wherein the steroid biosynthesis knock down nucleic acid reduces the expression of a gene selected from the group CYP21A2, CYP11A1, CYP17A1, CYP19A1, 3-?HSD1, 3-?HSD2, 17-?HSD1, StAR, HMGR, CYP11B2, CYP11B1, 5?-Reductase 2, SULT1E1, CYP3A4 and UTG1A1, wherein the cell comprises reduced expression of one or more of said genes. The cells are useful for identifying endocrine disruptors. Accordingly, the disclosure includes in a further aspect a screening assay for identifying an endocrine disruptor comprising: a) contacting a cell described herein with a test substance; b) determining a level of at least one steroid or steroidogenic gene mRNA or enzyme activity; wherein a modulation in the level of the at least one steroid or steroidogenic gene mRNA or enzyme activity compared to a control is indicative that the test substance is an endocrine disruptor.Type: GrantFiled: September 14, 2012Date of Patent: August 6, 2013Assignee: University of SaskatchewanInventors: Xiaowei Zhang, Markus Hecker, John P. Giesy
-
Patent number: 8501703Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.Type: GrantFiled: August 29, 2006Date of Patent: August 6, 2013Assignees: Isis Pharmaceuticals, Inc., Sarepta TherapeuticsInventors: C. Frank Bennett, Nicholas M. Dean, Ryszard Kole, Casey C. Kopczynski
-
Patent number: 8501705Abstract: Disclosed are methods for treating an autoimmune and/or complement mediated disease or condition in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Compositions which include inhibitors of C1q, C1r, C1s, C2 or C4 and a pharmaceutically acceptable excipient are also described.Type: GrantFiled: December 23, 2010Date of Patent: August 6, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Premkumar Christadoss, Erdem Tuzun
-
Publication number: 20130195819Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.Type: ApplicationFiled: March 27, 2013Publication date: August 1, 2013Applicant: The U.S.A , as represented by the Secretary, Department of Health and Human ServicesInventor: The United States of America, as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130195870Abstract: The present invention concerns somatic ErbB3 mutations in cancer including methods of identifying, diagnosing, and prognosing ErbB3 cancers, as well as methods of treating cancer, including certain subpopulations of patients.Type: ApplicationFiled: November 29, 2012Publication date: August 1, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Publication number: 20130195880Abstract: Provided are methods and kits to determine whether a subject is predisposed to developing a disease or condition associated with structural polymorphisms in genes CNTNAP2 and CNTNAP4, along with the methods to optimize treatment with various pharmaceutical preparations which modulate ion channels, neurite outgrowth, and myelination signaling.Type: ApplicationFiled: August 5, 2010Publication date: August 1, 2013Inventors: Leonid Z. Iakoubov, Henry Wilfred Lopez, Steven Patrick Noonan
-
Patent number: 8497251Abstract: A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-I?B? agent, an anti-I?B? agent or both; and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating latent HIV infection is also disclosed.Type: GrantFiled: May 29, 2012Date of Patent: July 30, 2013Assignee: Children's Research Institute, Children's National Medical CenterInventors: Steven L. Zeichner, Guerau Fernandez
-
Publication number: 20130189683Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: February 15, 2013Publication date: July 25, 2013Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, IGR&D SA, UNIVERSITE PARIS-SUD, INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES - ST QUENTIN EN YVELINES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Assistance Publique - Hopitaux De Paris, IGR&D SA, Institut National De La Sante Et De La Recherche Medicale (INSERM), Institut Gustave-Roussy, Universite De Versailles - St Quentin En Yvelines, Universite Paris-Sud
-
Publication number: 20130189243Abstract: The present invention provides methods and compositions for the diagnosis of acute ischemic stroke. The invention further provides methods and compositions for distinguishing acute ischemic stroke from other forms of stroke and TIAs and “stroke mimic” events. Moreover, methods and compositions are provided to facilitate the treatment of acute ischemic stroke patients.Type: ApplicationFiled: February 22, 2011Publication date: July 25, 2013Inventors: Taura L. Barr, Maria Del Mar Matarin, Steven Jay Warach, Andrew Barry Singleton, Yvette P. Conley
-
Publication number: 20130190200Abstract: The present invention relates to a single nucleotide polymorphism (SNP) for predicting the sensitivity to an anticancer targeted therapeutic formulation, a polynucleotide containing the same, and a method for predicting the sensitivity to an anticancer targeted therapeutic formulation. According to the present invention, it is possible to predict the sensitivity of each individual to a certain anticancer targeted therapeutic formulation, using a small amount of a sample taken from a patient and thus to select a most suitable targeted therapeutic formulation over the entire duration of treatment for the patient.Type: ApplicationFiled: December 8, 2010Publication date: July 25, 2013Applicants: Korea Research Institute of Bioscience and Biotechnology, The ASAN FoundationInventors: Jin Cheon Kim, Yong Sung Kim, Seon Young Kim, Dong Hyung Cho
-
Publication number: 20130190386Abstract: MicroRNA profiles transition from normal breast to ductal carcinoma in situ and transition to invasive ductal carcinoma (IDC) and methods of use thereof are described. Methods of diagnosis and prognosis using microRNA signatures to differentiate invasive from in situ carcinoma are described. Also described is the use of microRNA expression for predicting overall survival and time to metastasis.Type: ApplicationFiled: January 22, 2013Publication date: July 25, 2013Applicant: The Ohio State UniversityInventor: The Ohio State University
-
Publication number: 20130190379Abstract: The invention is related to small RNA molecules, precursors thereof and methods for detecting such molecules. The invention is in particular concerned with differentially expressed small RNA molecules and precursors thereof. Various collections of small RNA molecules, precursors thereof and collections of probe and primers that can be used to detect small RNA molecules, precursors thereof are provided. Further provided are diagnostic test based on this differential expression. Also provided are therapeutic applications using one or more of the members of the presented collections.Type: ApplicationFiled: July 7, 2008Publication date: July 25, 2013Inventors: Edwin Pieter Johan Cuppen, Gerrit Albert Meijer, Eugene Berezikov, Maria Begona Diosdado Calvo
-
Patent number: 8492094Abstract: The invention provides a method of detecting a nucleic acid analyte. The method consists of (a) contacting a mixture of nucleic acid analytes under conditions sufficient for hybridization with a plurality of target specific nucleic acid probes each having a different specifier; (b) contacting the mixture under conditions sufficient for hybridization with a corresponding plurality of antigenedigits each having a unique label, the plurality of anti-genedigits having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) uniquely detecting a hybridized complex between one or more analytes in the mixture, a target specific probe, and an anti-genedigit.Type: GrantFiled: February 15, 2011Date of Patent: July 23, 2013Assignee: The Institute for Systems BiologyInventors: Krassen Dimitrov, Dwayne L. Dunaway
-
Patent number: 8492357Abstract: The present invention relates to the modulation of immunoregulatory proteins, including cytokines, such as colony stimulatory factors (CSF) via the use of microRNA-155 modulators.Type: GrantFiled: July 24, 2009Date of Patent: July 23, 2013Assignee: Santaris Pharma A/SInventors: Jesper Worm, Jan Stenvang, Susanna Obad, Sakari Kauppinen
-
Patent number: 8492083Abstract: Described herein is a method of decreasing expression of HOXA1 in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.Type: GrantFiled: August 27, 2012Date of Patent: July 23, 2013Assignee: The Ohio State UniversityInventors: Carlo M. Croce, Ramiro Garzon, George A. Calin
-
Patent number: 8492534Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.Type: GrantFiled: November 30, 2007Date of Patent: July 23, 2013Assignee: The University of British ColumbiaInventors: Martin Gleave, Palma Rocchi, Maxim Signaevsky, Eliana Beraldi
-
Publication number: 20130183317Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.Type: ApplicationFiled: March 13, 2013Publication date: July 18, 2013Applicant: Temple University of the Commonwealth System of Higher EducationInventor: Temple University of the Commonwealth System of Higher Education
-
Patent number: 8486907Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.Type: GrantFiled: October 11, 2011Date of Patent: July 16, 2013Assignee: The University of Western AustraliaInventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
-
Patent number: 8486909Abstract: Compositions and methods are disclosed for the treatment and diagnosis of inflammatory diseases and disorders, including pulmonary diseases and fibrotic disorders, including COPD.Type: GrantFiled: June 24, 2010Date of Patent: July 16, 2013Assignee: Board of Regents of the University of NebraskaInventors: Stephen I. Rennard, Tadashi Sato, Xiang-der Liu, Olaf Holz, Helgo Magnussen
-
Patent number: 8486912Abstract: Described herein is a method of decreasing expression of MAFB in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a MAFB gene product where an effective amount of at least one miR-130a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the MAFB gene product in the subject.Type: GrantFiled: August 27, 2012Date of Patent: July 16, 2013Assignee: The Ohio State University Research FoundationInventors: Carlo M. Croce, Ramiro Garzon, George A. Calin
-
Patent number: 8486913Abstract: Described herein is a method of decreasing expression of HOXA1 in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.Type: GrantFiled: August 27, 2012Date of Patent: July 16, 2013Assignee: The Ohio State UniversityInventors: Carlo M. Croce, Ramiro Garzon, George A. Calin
-
Publication number: 20130177908Abstract: The present disclosure provides probes for detecting a polymorphism in the PON1 gene.Type: ApplicationFiled: January 10, 2013Publication date: July 11, 2013Applicant: ARKRAY, Inc.Inventors: Kaoru Kurose, Mariko Komori
-
Publication number: 20130178379Abstract: Markers of caloric restriction (CR) can be identified in a selected tissue by exposing an animal to CR conditions and selecting one or more genes differentially expressed in response to CR conditions in multiple subject groups. A candidate compound can be screened for likely ability to mimic the effects of CR when administered to an animal by comparing the tissue levels of expression products of the genes in animals treated with the candidate compound to those of animals subjected to CR.Type: ApplicationFiled: June 15, 2012Publication date: July 11, 2013Applicant: NSE Products, Inc.Inventors: Angela Mastaloudis, Steve Wood, Tomas Alberto Prolla, Jamie Louis Barger, Richard Weindruch, Joseph Chang
-
Patent number: 8481700Abstract: An oligonucleotide, primer or probe comprises the nucleotide sequences of any of SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 25. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular the MAGE-A3 gene. The oligonucleotides are useful in primer pairs, kits and methods for determining the methylation status of the MAGE-A3 gene and for diagnosing cancer, directing therapy and selecting subjects for treatment. The primer or probe can comprise a loop or hairpin structure and can be used in real-time methylation specific PCR.Type: GrantFiled: September 17, 2008Date of Patent: July 9, 2013Assignees: MDxHealth SA, GlaxoSmithKline Biologicals SAInventors: Ilse Vlassenbroeck, Katja Bierau
-
Patent number: 8481710Abstract: The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules.Type: GrantFiled: December 9, 2010Date of Patent: July 9, 2013Assignee: University of Iowa Research FoundationInventors: Beverly L. Davidson, Haibin Xia, Qinwen Mao, Henry Paulson, Ryan Boudreau, Scott Harper
-
Publication number: 20130171642Abstract: The disclosure provides methods for automated characterization of circulating tumor cells (CTCs), for example using automated tissue strainers. In specific examples, such methods permit characterizing a prostate cancer sample by simultaneously or contemporaneously detecting ERG rearrangements and PTEN deletions in the same CTC. Also provided are kits that can be used with such methods.Type: ApplicationFiled: December 28, 2012Publication date: July 4, 2013Inventors: Gary Pestano, Ryan Dittamore, Karl Garsha, Michael Otter, Chol Steven Yun, Alexandra Dea Nagy
-
Patent number: 8476020Abstract: Genetic variants in the BRCA2 gene are disclosed which are useful as diagnosis biomarkers.Type: GrantFiled: June 23, 2011Date of Patent: July 2, 2013Assignee: Myriad Genetics, Inc.Inventors: Thomas Scholl, Brian E. Ward, Amie Deffenbaugh, Lynn Burbidge, Walter W. Noll
-
Patent number: 8476245Abstract: The presently disclosed subject matter provides DNA molecules designed to down regulate the expression of MMP genes in a cell. Also provided are compositions comprising the DNA molecules. The presently disclosed subject matter further provides methods of using the DNA molecules to inhibit metastasis of a cancer cell. The presently disclosed subject matter also provides methods of using the DNA molecules to modulate tumor growth in a subject.Type: GrantFiled: February 23, 2009Date of Patent: July 2, 2013Assignee: University of Tennessee Research FoundationInventors: Tayebeh Pourmotabbed, Hisashi Hasegawa, Chad Batson
-
Patent number: 8476421Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.Type: GrantFiled: February 22, 2010Date of Patent: July 2, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, James G. Karras
-
Patent number: 8476423Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.Type: GrantFiled: October 11, 2011Date of Patent: July 2, 2013Assignee: The University of Western AustrailiaInventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
-
Patent number: 8470796Abstract: Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide.Type: GrantFiled: April 15, 2011Date of Patent: June 25, 2013Assignee: The University of British ColumbiaInventor: Martin E. Gleave
-
Publication number: 20130157883Abstract: The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of an acute coronary syndrome in a blood sample from a human. Further, the present invention relates to means for diagnosing and/or prognosing of an acute coronary syndrome comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of an acute coronary syndrome based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome compared to a reference. In addition, the present invention relates to a kit for diagnosing and/or prognosing of an acute coronary syndrome comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome and at least one reference.Type: ApplicationFiled: April 19, 2011Publication date: June 20, 2013Applicant: FEBIT HOLDING GMBHInventors: Andreas Keller, Peer F. Stähler, Markus Beier, Benjamin Meder, Hugo A. Katus, Wolfgang Rottbauer
-
Publication number: 20130158095Abstract: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.Type: ApplicationFiled: May 10, 2012Publication date: June 20, 2013Applicants: CureGene K.K., Astellas Pharma Inc.Inventors: Hiroyuki Mano, Sadao Kuromitsu, Nobuaki Shindo, Takatoshi Soga, Takashi Furutani
-
Publication number: 20130157886Abstract: Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided.Type: ApplicationFiled: November 26, 2012Publication date: June 20, 2013Inventors: Bernard MICHOT, Olivier DELFOUR, David H. PERSING
-
Publication number: 20130157873Abstract: Methods of using single nucleotide polymorphisms (SNPs), SNP haplotype block, and haplotype to predict whether or not a subject will develop necrotizing meningoencephalitis (NME) and probe sets that facilitate those methods are disclosed. In particular, the subject is a canine species.Type: ApplicationFiled: May 19, 2011Publication date: June 20, 2013Applicant: TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Matthew Huentelman, Scott Schatzberg, Renee Barber
-
Patent number: 8466273Abstract: The present invention aims to provide hepatitis C virus inhibitors capable of inhibiting viral replication in hepatitis C virus-infected cells. The replication of hepatitis C virus can be inhibited and hepatitis C virus-infected cells can be specifically injured by specifically inhibiting BGT-1 or AKR1C1 involved in the replication of hepatitis C virus. Thus, viral inhibitors comprising a substance inhibiting BGT-1 or AKR1C1 are effective for the treatment of hepatitis C.Type: GrantFiled: September 30, 2008Date of Patent: June 18, 2013Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Tokyo Metropolitan Institute of Medical Science, National University Corporation Kumamoto UniversityInventors: Kyoko Kohara, Michinori Kohara, Tomohiro Nishimura, Masaaki Sato
-
Patent number: 8466274Abstract: Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that target human cyclophilin A (CyPA) to inhibit Hepatitis C (HCV) infection. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.Type: GrantFiled: October 2, 2012Date of Patent: June 18, 2013Assignee: Florida State University Research FoundationInventor: Hengli Tang
-
Patent number: 8465923Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA 112, CSPG2, TLR2, and CD163.Type: GrantFiled: December 16, 2011Date of Patent: June 18, 2013Assignee: National Jewish HealthInventors: Milene Saavedra, Jerry Nick
-
Patent number: 8465914Abstract: The present invention concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the present invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.Type: GrantFiled: July 2, 2012Date of Patent: June 18, 2013Assignee: Asuragen, Inc.Inventors: David Brown, Rick Conrad, Eric Devroe, Marianna Goldrick, Kerri Keiger, Emmanuel Labourier, Ivonne Moon, Patricia Powers, Jeffrey Shelton, Jaclyn Shingara
-
Publication number: 20130149319Abstract: Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).Type: ApplicationFiled: May 28, 2010Publication date: June 13, 2013Applicant: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCESInventors: Jae-Seon Lee, Bong Cho Kim, Je-Jung Lee, Su Min Park
-
Publication number: 20130149711Abstract: The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.Type: ApplicationFiled: August 17, 2011Publication date: June 13, 2013Applicants: HOPITAUX UNIVERSITAIRES DE GENEVE, UNIVERSITE DE GENEVEInventors: Irmgard Irminger-Finger, Yong-Qiang Zhang
-
Publication number: 20130150426Abstract: Described herein are materials and methods for the diagnosis of idiopathic pulmonary fibrosis.Type: ApplicationFiled: November 21, 2012Publication date: June 13, 2013Applicant: INTERMUNE, INC.Inventor: INTERMUNE, INC.
-
Patent number: 8461325Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.Type: GrantFiled: November 30, 2011Date of Patent: June 11, 2013Assignee: Royal Holloway, University of LondonInventors: Linda Popplewell, Ian Graham, John George Dickson
-
Patent number: 8460924Abstract: The present invention relates to nucleic acid molecule compositions comprising MiniVectors™ encoding a nucleic acid sequence and methods of gene therapy using MiniVectors encoding a nucleic acid sequence.Type: GrantFiled: October 15, 2010Date of Patent: June 11, 2013Assignee: Baylor College of MedicineInventors: E. Lynn Zechiedrich, Jonathan Fogg, Daniel James Catanese, Jr., Erol Bakkalbasi, Brian E. Gilbert
-
Publication number: 20130143748Abstract: Provided is a method of measuring the expression level of FSTL3 gene in a biological sample and correlating the measured expression level with the detection of a risk of developing diabetes. Also provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 not clinically determined as obesity and correlating the measured expression level with the detection of a risk of developing obesity. Further provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 and correlating the measured expression level with the detection of a risk of developing diabetes. Further provided is a method of measuring an inhibin ?B gene expression level and correlating the ratio of expression level of FSTL3 gene to inhibin ?B gene with the detection of a risk of developing obesity or diabetes.Type: ApplicationFiled: May 27, 2011Publication date: June 6, 2013Applicants: SEKISUI MEDICAL CO., LTD., THE UNIVERSITY OF TOKYOInventors: Takashi Kadowaki, Kohjiro Ueki, Yukiko Okazaki, Matthias Bluher, Sumiko Ozawa
-
Patent number: 8455635Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.Type: GrantFiled: October 11, 2011Date of Patent: June 4, 2013Assignee: The University of Western AustraliaInventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
-
Patent number: 8455634Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.Type: GrantFiled: June 24, 2011Date of Patent: June 4, 2013Assignee: The University of Western AustraliaInventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey